Nisa Investment Advisors LLC Sells 98 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Nisa Investment Advisors LLC cut its position in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,137 shares of the company’s stock after selling 98 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Shockwave Medical were worth $407,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of SWAV. Lindbrook Capital LLC increased its position in shares of Shockwave Medical by 64.8% during the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Shockwave Medical by 297.4% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock worth $31,000 after acquiring an additional 116 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in Shockwave Medical during the 4th quarter worth approximately $34,000. PenderFund Capital Management Ltd. bought a new position in Shockwave Medical during the 1st quarter worth approximately $41,000. Finally, Operose Advisors LLC bought a new position in Shockwave Medical during the 3rd quarter worth approximately $49,000. 95.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SWAV shares. CL King restated a “neutral” rating on shares of Shockwave Medical in a research report on Monday, April 8th. Morgan Stanley reiterated an “equal weight” rating and issued a $335.00 price objective (up from $285.00) on shares of Shockwave Medical in a research report on Monday, April 8th. Canaccord Genuity Group reiterated a “hold” rating and issued a $335.00 price objective (up from $263.00) on shares of Shockwave Medical in a research report on Friday, April 5th. Leerink Partnrs lowered Shockwave Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, April 5th. Finally, SVB Leerink reiterated a “market perform” rating and issued a $335.00 price objective (down from $361.00) on shares of Shockwave Medical in a research report on Monday, April 8th. Ten analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $309.11.

Insider Buying and Selling at Shockwave Medical

In other Shockwave Medical news, CEO Douglas Evan Godshall sold 10,000 shares of Shockwave Medical stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $231.56, for a total transaction of $2,315,600.00. Following the completion of the transaction, the chief executive officer now owns 162,762 shares in the company, valued at $37,689,168.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Shockwave Medical news, CEO Douglas Evan Godshall sold 10,000 shares of Shockwave Medical stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $231.56, for a total transaction of $2,315,600.00. Following the completion of the transaction, the chief executive officer now owns 162,762 shares in the company, valued at $37,689,168.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Laura Francis sold 1,500 shares of Shockwave Medical stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $300.00, for a total value of $450,000.00. Following the transaction, the director now owns 3,551 shares of the company’s stock, valued at approximately $1,065,300. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 93,813 shares of company stock worth $23,762,679. 3.40% of the stock is owned by insiders.

Shockwave Medical Stock Performance

SWAV opened at $327.50 on Thursday. The stock has a market cap of $12.25 billion, a PE ratio of 84.63, a PEG ratio of 2.43 and a beta of 0.92. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09. The business has a 50 day moving average of $282.20 and a 200-day moving average of $227.08. Shockwave Medical, Inc. has a 52 week low of $157.00 and a 52 week high of $331.58.

Shockwave Medical (NASDAQ:SWAV) last released its earnings results on Thursday, February 15th. The company reported $1.16 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. The company had revenue of $202.98 million during the quarter, compared to analysts’ expectations of $199.43 million. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The firm’s revenue for the quarter was up 41.0% compared to the same quarter last year. During the same quarter last year, the business posted $3.71 EPS. Equities research analysts predict that Shockwave Medical, Inc. will post 4.94 earnings per share for the current fiscal year.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.